What Teturam Tablets Treats: Main Uses and Benefits

Teturam (Disulfiram) is a medication applied in the management of Alcohol Use Disorder (AUD), offering a pharmacological intervention to support the patient's recovery goals. This medication is commonly used in clinical practice when patients are committed to staying away from alcohol.

It is primarily relevant in contexts marked by chronic alcoholism and alcohol dependence, targeting the patient's inability to sustain abstinence and high relapse vulnerability. The key therapeutic benefit is that it is commonly used to help with a strong deterrent effect. The medication supports patients who are striving to maintain sobriety.

Quick Fact: Use in Compulsive Drinking Patterns

Aspect	Description
Primary Use	Deterrent to alcohol consumption
Targeted Condition	Chronic Alcoholism / Alcohol Dependence
Targeted Symptom Pattern	Compulsive seeking and use of alcohol
Clinical Context	Long-term support for abstinence

The medication is applied in addressing these conditions in clinical settings marked by high risk, helping patients cope more steadily with symptom fluctuations. The supportive nature of the treatment assists with maintaining functional stability, and this approach plays a role in managing the pervasive pattern of relapse vulnerability, contributing to easing the overall symptom load of the compulsion to drink.

Regulatory References

1. NIH MedlinePlus overview of AUD treatment

Official Eligibility and Contraindications

The use of Teturam (Disulfiram) tablets is governed by strict regulatory eligibility rules that define who can and cannot take the medicine, primarily based on underlying health conditions and concurrent substance use.

Absolute Contraindications (Must Not Use):

Condition / Status	Restriction
Concurrent Substances	Recent ingestion of alcohol or alcohol-containing preparations (within 12 hours), metronidazole, or paraldehyde.
Underlying Diseases	Severe myocardial disease, coronary occlusion, or psychoses.
Allergy	Known hypersensitivity to Disulfiram or related thiuram derivatives.

Restricted or Conditional Use (Use with Extreme Caution):

The medicine's label advises extreme caution and careful consideration in patients with severe hepatic cirrhosis or insufficiency, diabetes mellitus, hypothyroidism, epilepsy or seizure disorders, and chronic or acute nephritis, as these conditions may increase the risk of severe reactions.

Special Population Status:

• Pediatric Use: Safety and effectiveness have not been established in children and adolescents.
• Pregnancy/Lactation: Safe use during pregnancy has not been established; use is only advised if benefits clearly outweigh risks. Use in nursing mothers is advised against.

Interactions with other medicines and products

Official regulatory documents define the interaction profile of Teturam (disulfiram) primarily through pharmacodynamic and pharmacokinetic mechanisms, imposing strict rules for co-administration.

Contraindicated Combinations

The co-administration of Teturam with ethanol (alcohol) in any form is strictly prohibited due to the risk of the severe Disulfiram-Alcohol Reaction. This restriction extends to alcohol-containing products (e.g., mouthwashes, cough syrups, topical rubs). The drug is also contraindicated with Metronidazole and Paraldehyde because of the documented risk of confusion and/or psychotic reactions.

Pharmacokinetic Interactions

Teturam is a documented inhibitor of certain hepatic microsomal enzymes (CYP450 system), leading to decreased metabolism and increased systemic exposure of several co-administered drugs. This requires careful monitoring and potential dose adjustment for agents such as:

• Oral Anticoagulants (e.g., Warfarin): Increased prothrombin time and bleeding risk.
• Anticonvulsants (e.g., Phenytoin): Elevated plasma concentrations and potential for toxicity.
• Theophylline and Tricyclic Antidepressants: Increased plasma concentrations due to reduced clearance.

Timing and Population Notes

Abstinence from alcohol is required for at least 12 to 24 hours before initiating treatment. Alcohol avoidance must continue for a minimum of 14 days after Teturam discontinuation, as the interaction risk persists. Dose selection in geriatric patients requires caution, reflecting the greater frequency of polypharmacy and potential for decreased organ function.

Teturam tablets, containing Disulfiram, operate by interfering with the physiological processes of ethanol catabolism, resulting in a profound systemic physiological consequence upon ethanol exposure. This mechanism is defined by two core domains: enzyme inhibition in the alcohol metabolism pathway and the subsequent modulation of specific neurochemical precursors.

---

Irreversible Inactivation of Alcohol Metabolism

This mechanism is centered on the irreversible inhibition of the enzyme Aldehyde Dehydrogenase ( ALDH), the primary target enzyme in the second step of ethanol metabolism. By permanently blocking ALDH, the drug causes the metabolite acetaldehyde to remain unprocessed and accumulate rapidly in the bloodstream when ethanol is present.

---

Generation of an Acute Systemic Physiological Cascade

The rapid buildup of systemic acetaldehyde triggers the main physiological consequences, as this compound is a potent systemic vasodilator. The resulting cascade involves an acute drop in vascular tone (hypotension), leading to marked flushing, and a reflex surge in heart rate (tachycardia). This domain links the molecular blockade to the resulting systemic physiological changes, characterizing the primary mechanism.

---

Ancillary Neurochemical Modulation

A secondary mechanistic domain involves the inhibition of Dopamine beta-Hydroxylase (DbetaH), the enzyme that converts Dopamine into Norepinephrine. This interaction alters the balance of these catecholamine neurotransmitters, which modulates the secondary physiological effects of the mechanism.

How to Use Teturam Tablets

Teturam (Disulfiram) is a medication administered orally as a single, once-daily dose, with the administration procedure strictly defined to ensure appropriate use. The drug is available as an oral tablet in 250 mg and 500 mg unit strengths, establishing the only approved route of intake.

---

Official Dosing Regimens and Schedule

Administration follows a structured two-phase regimen. The initial dose is set at a maximum of 500 mg once daily, typically for the first one to two weeks of therapy. This is followed by a maintenance dose which averages 250 mg daily, though the official range allows for 125 mg to 500 mg daily, and the maximum daily dose must not be exceeded. The medication is generally taken in the morning, but may be shifted to bedtime if the patient experiences a sedative effect.

---

Administration Conditions and Duration

A critical procedural condition is the pre-dose abstinence requirement: the drug must not be administered until the patient has achieved at least 12 hours of confirmed abstinence from alcohol. The tablet may be crushed and mixed with liquids (such as water or juice) if swallowing is difficult, and taking it with food may help reduce potential stomach upset. Teturam is intended for long-term, sustained administration—typically continuing uninterrupted for months or even years to support treatment goals.

Handling and Special Use

In cases where a dose is missed, patients are instructed to take the dose as soon as remembered, but to skip the missed dose if it is almost time for the next scheduled dose, strictly avoiding a double dose. For older adults, guidelines recommend careful dosage selection, often initiating treatment at the lower end of the official range.

Clinical Research Summary

Teturam (generic name: disulfiram) has been used for decades to support the treatment of alcohol use disorder (AUD). Its primary function is to act as a deterrent; it does not treat withdrawal symptoms or reduce alcohol cravings directly. Its effectiveness is closely related to its use within a comprehensive treatment program, including counseling and behavioral therapies.

Research regarding the efficacy of disulfiram is often framed around the importance of adherence, which is typically managed through supervised administration.

• Supervised Treatment: Multiple randomized controlled trials (RCTs) suggest that when disulfiram use is supervised by a healthcare provider or a committed individual, it is associated with significantly higher rates of short-term abstinence and an increased number of days until relapse compared to unsupervised use. The variation in outcomes across these studies highlights the critical role of patient adherence and the context of care.

• Unsupervised Use: Trials of unsupervised disulfiram use, particularly those using blinded, placebo-controlled designs, often found no statistically significant difference in continuous abstinence rates between the active drug and control groups.

• Long-Term Outcomes: Evidence regarding the drug's impact on long-term abstinence (beyond 12 months) remains mixed, making its use generally recommended as part of a sustained, multifaceted treatment plan.

Safety and Tolerability

Disulfiram is generally tolerated by most patients; however, its effects if alcohol is consumed are severe. Side effects reported in trials, separate from an alcohol reaction, are typically mild and transient, including a metallic or garlic-like taste, headache, and fatigue. The risk of rare but serious adverse events, such as hepatotoxicity (liver injury) and peripheral neuropathy (nerve damage), is a factor that is monitored closely by healthcare providers, particularly in patients with pre-existing conditions.

Key Studies & References

1. NICE Guideline NG13: Alcohol-use disorders: prevention and early intervention

Common questions about Teturam tablets (FAQ)

---

Q: Will this medicine interact with my blood pressure medication?

Official product information suggests a theoretical interaction when Teturam is taken with certain other medicines that affect liver enzymes. These effects could impact how other drugs are processed by the body. Patients are advised to consult the 'Drug Interactions' section of the medicine's label to check for their specific blood pressure medication.

Q: Does this medication cause weight changes?

Regulatory documents, such as the Summary of Product Characteristics (SmPC), indicate that changes in weight have been reported as an undesirable effect. Specifically, weight gain was noted as an adverse reaction during the clinical trials that studied the medicine. This information is typically found in the section listing known side effects.

Q: What should I do if I miss a dose?

The official instructions regarding a missed dose indicate that the typical regulatory instruction is to take the dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the official guidance directs that the missed dose should be skipped completely. It is also stated that two doses should not be taken at the same time to compensate for the missed one.

Q: How long does the drug stay in my system after the last dose?

According to the pharmacokinetics data in the official prescribing information, the medicine has a terminal plasma half-life of approximately 12–15 hours. The half-life is a measure of the time it takes for the concentration of the drug in the body to be reduced by half. This value helps determine the general timeline for how long the drug remains active in your system after the final dose.

Q: Can children younger than 12 use this drug?

The official regulatory documents, including the Patient Information Leaflet and Contraindications section, state that the use of Teturam tablets is not recommended in children younger than 12 years of age. This limitation is based on the information and studies available during the regulatory approval process.

How to Store and Dispose of Teturam tablets

The official labeled requirements for storing Teturam (disulfiram) tablets are essential for maintaining the product's stability and ensuring safety. Regulatory documents specify that the tablets must be stored at Controlled Room Temperature, typically maintained between 20 C and 25 C (68 F and 77 F).

Storage and Protection Rules

• Keep the tablets in the original container and ensure the container is tightly closed.
• The medication must be protected from light and excess moisture.
• Always store Teturam tablets strictly out of the sight and reach of children.

Disposal Requirements

To prevent environmental contamination, official regulations prohibit disposing of any unused or expired Teturam tablets via wastewater (e.g., flushing the toilet) or household waste. Instead, the medicine should be discarded according to local requirements, often utilizing a drug take-back program or specialized authorized disposal procedures.